Ernexa Therapeutics Inc. (ERNA) bonds
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.79−0.14 (-7.25%)
Close on Nov 12, 2026Market cap $2.92MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Ernexa Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2018
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Ernexa Therapeutics's 10-Q for the period ended Mar 21, 2025
| Issue | Amount issued |
|---|---|
| Promissory Note One Convertible | $1.50M |
| Promissory Note Two Convertible | $800.00K |
| Two Promissory Note Convertible | $2.30M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?